Diagenode

Global distribution of DNA hydroxymethylation and DNA methylation in chronic lymphocytic leukemia.


Wernig-Zorc S, Yadav MP, Kopparapu PK, Bemark M, Kristjansdottir HL, Andersson PO, Kanduri C, Kanduri M

BACKGROUND: Chronic lymphocytic leukemia (CLL) has been a good model system to understand the functional role of 5-methylcytosine (5-mC) in cancer progression. More recently, an oxidized form of 5-mC, 5-hydroxymethylcytosine (5-hmC) has gained lot of attention as a regulatory epigenetic modification with prognostic and diagnostic implications for several cancers. However, there is no global study exploring the role of 5-hydroxymethylcytosine (5-hmC) levels in CLL. Herein, using mass spectrometry and hMeDIP-sequencing, we analysed the dynamics of 5-hmC during B cell maturation and CLL pathogenesis. RESULTS: We show that naïve B-cells had higher levels of 5-hmC and 5-mC compared to non-class switched and class-switched memory B-cells. We found a significant decrease in global 5-mC levels in CLL patients (n = 15) compared to naïve and memory B cells, with no changes detected between the CLL prognostic groups. On the other hand, global 5-hmC levels of CLL patients were similar to memory B cells and reduced compared to naïve B cells. Interestingly, 5-hmC levels were increased at regulatory regions such as gene-body, CpG island shores and shelves and 5-hmC distribution over the gene-body positively correlated with degree of transcriptional activity. Importantly, CLL samples showed aberrant 5-hmC and 5-mC pattern over gene-body compared to well-defined patterns in normal B-cells. Integrated analysis of 5-hmC and RNA-sequencing from CLL datasets identified three novel oncogenic drivers that could have potential roles in CLL development and progression. CONCLUSIONS: Thus, our study suggests that the global loss of 5-hmC, accompanied by its significant increase at the gene regulatory regions, constitute a novel hallmark of CLL pathogenesis. Our combined analysis of 5-mC and 5-hmC sequencing provided insights into the potential role of 5-hmC in modulating gene expression changes during CLL pathogenesis.

Tags
MagMeDIP kit
Antibody

Share this article

Published
January, 2019

Source

Products used in this publication

  • RFX5-polyclonal-antibody-diagenode
    C15200081-100
    5-methylcytosine (5-mC) monoclonal antibody 33D...
  • RFX5-polyclonal-antibody-diagenode
    C15220001-50
    5-hydroxymethylcytosine (5-hmC) monoclonal anti...
  • Antibody ChIP-seq grade icon
    C15410174
    H3K27ac polyclonal antibody
  • Antibody ChIP-seq grade icon
    C15410037-50
    H3K4me1 polyclonal antibody - Classic
  • ChIP kit icon
    C01010080
    OneDay ChIP kit
  • Methylation kit icon
    C02010030
    hMeDIP kit x16 (monoclonal rat antibody)
  • MagMeDIP qPCR Kit box
    C02010021
    MagMeDIP qPCR Kit

Events

 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.



  ABOUT SSL CERTIFICATES

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics